ERBB2 and ductal breast carcinoma in situ: A clinical trial previously found that anti-HER2 dendritic cell vaccination could induce a tumor-specific T cell reaction, resulting in improved outcomes in patients with HER2-positive DCIS.344 Although HER2 receptor-targeted therapy is the standard in HER2-positive IDC, its role in HER2-positive DCIS needs further validation.